A combination of genetic and functional approaches has identified three independent breast cancer risk loci at 2q35. Advances in the evaluation and treatment of breast cancer have made the clinical decision-making context much more complex. Participants were followed for on average 11.45 years and there were 416 incident breast cancers. For equivalent sensitivities, the 5-year incidence almost always had higher specificities than lifetime risk from birth. This Phase Ib-IIa, multi-institutional, open-label, dose-escalation study is designed to View details for DOI 10.1007/s10549-012-2329-5, View details for Web of Science ID 000312710500023, View details for DOI 10.1007/s10549-012-2292-1, View details for Web of Science ID 000312071000033, View details for PubMedCentralID PMC3511694, View details for DOI 10.1007/s12609-012-0091-7, View details for Web of Science ID 000219327600002. We compared breast cancer incidence and proportion of newly diagnosed patients receiving pre-operative systemic therapy pre-COVID, in the first 2 months of the COVID pandemic and in the later part of the COVID pandemic.Average monthly breast cancer incidence was 19.3 (95% CI 19.1-19.5) cases per 100,000 women and men pre-COVID, 11.6 (95% CI 10.8-12.4) per 100,000 in April-May 2020, and 19.7 (95% CI 19.3-20.1) per 100,000 in June 2020-February 2021. NAC use more than doubled over time and increased with stage (Stage I, 0.7%; Stage III, 29.9%). My research employs methods from the population sciences, in collaboration the Surveillance, Epidemiology and End Results (SEER) Program. Relationships between sociodemographic and clinical factors and GCC receipt differed by subtype. In 2016, my wife and I had our first child, Antalya. Understanding of risk and patient factors (e.g. Friese, C., Li, Y., Kurian, A. W., Katz, S. J. Prevalence and consequences of second opinions from medical oncologists for early-stage breast cancer: Results from the iCanCare study. Parikh, D. A., Dickerson, J. C., Kurian, A. W. Combined associations of a polygenic risk score and classical risk factors with breast cancer risk. their breast cancer risk. Jagsi, R., Griffith, K. A., Kurian, A. W., Morrow, M., Hamilton, A. S., Graff, J. J., Katz, S. J., Hawley, S. T. Intersection of Race/Ethnicity and Socioeconomic Status in Mortality After Breast Cancer. Scott, D. n., Friedman, S. n., Telli, M. L., Kurian, A. W. Modeling reductions in absolute cancer mortality from diagnosing cancers before metastasis, 2006-2015. J. Surg. View details for PubMedCentralID PMC7785044, View details for DOI 10.1093/jncics/pkaa083, View details for PubMedCentralID PMC7785044. Large-scale analysis of real-world evidence is often limited to structured data fields that do not contain reliable information on recurrence status and disease sites. Patients who had genetic counseling were twice as likely to recall clinicians informing them about all queried topics. is to compare efficacy and safety of a treatment with exemestane + everolimus to exemestane + Katz, S. J., Tocco, R., Hawley, S. T., An, L., Hodan, R., Ward, K. C., Kurian, A. W. Association of germline genetic testing results with chemotherapy regimens received by women with early-stage breast cancer. Financial toxicity subgroups were compared based on a validated grading system.Participants (N=273; 74% breast cancer) averaged 54.65 years (SD=12.08), were 3.42 years (SD=4.20) post-diagnosis, and 33% reported cancer-related change in employment status. All four cases with MLH1/PMS2 protein loss had MLH1 promotor hypermethylation. Chen, H., Fan, S., Stone, J., Thompson, D. J., Douglas, J., Li, S., Scott, C., Bolla, M. K., Wang, Q., Dennis, J., Michailidou, K., Li, C., Peters, U., Hopper, J. L., Southey, M. C., Nguyen-Dumont, T., Nguyen, T. L., Fasching, P. A., Behrens, A., Cadby, G., Murphy, R. A., Aronson, K., Howell, A., Astley, S., Couch, F., Olson, J., Milne, R. L., Giles, G. G., Haiman, C. A., Maskarinec, G., Winham, S., John, E. M., Kurian, A., Eliassen, H., Andrulis, I., Evans, D. G., Newman, W. G., Hall, P., Czene, K., Swerdlow, A., Jones, M., Pollan, M., Fernandez-Navarro, P., McConnell, D. S., Kristensen, V. N., Rothstein, J. H., Wang, P., Habel, L. A., Sieh, W., Dunning, A. M., Pharoah, P. D., Easton, D. F., Gierach, G. L., Tamimi, R. M., Vachon, C. M., Lindstrm, S. Trends in Annual Surveillance Mammography Participation Among Breast Cancer Survivors From 2004 to 2016. Jagsi, R., Abrahamse, P., Lee, K., Wallner, L. P., Janz, N. K., Hamilton, A. S., Ward, K. C., Morrow, M., Kurian, A. W., Friese, C., Hawley, S. T., Katz, S. J. On multivariable analysis, factors associated with CPM included younger age (per 5-year increase: odds ratio [OR], 0.71; 95% CI, 0.65-0.77), white race (black vs white: OR, 0.50; 95% CI, 0.34-0.74), higher educational level (OR, 1.69; 95% CI, 1.20-2.40), family history (OR, 1.63; 95% CI, 1.22-2.17), and private insurance (Medicaid vs private insurance: OR, 0.47; 95% CI, 0.28-0.79). In multivariate modeling, worse sexual function and greater unmet sexuality needs related to greater distress. The objective of this study was to assess patients' perspectives regarding the impact of COVID-19 on their experiences, including their cancer care, emotional and mental health, and social determinants of health, and to evaluate whether these outcomes differed by cancer stage.MATERIALS AND METHODS: We conducted a survey among adults with cancer across the United States from April 1, 2020 to August 26, 2020 using virtual snowball sampling strategy in collaboration with professional organizations, cancer care providers, and patient advocacy groups. Methylated BRCA1 alleles were present in 194 controls (5.5%). women with triple negative breast cancer whose tumors are positive for a defined pattern of View details for DOI 10.1080/13691058.2014.939227, View details for Web of Science ID 000342208800012. Existing research examining barriers to addressing patients' sexual health concerns has focused on discrete characteristics of the provider-patient interaction without considering the broader context in which these interactions occur. One-third (33%) received chemotherapy. (PsycInfo Database Record (c) 2022 APA, all rights reserved). While these tests may identify 40% to 50% more individuals with hereditary cancer gene mutations than does testing for BRCA1/2 alone, whether finding such mutations will alter clinical management is unknown.To define the potential clinical effect of multigene panel testing for HBOC in a clinically representative cohort.Observational study of patients seen between 2001 and 2014 in 3 large academic medical centers. He reports to Oracle's executive chairman and CTO Larry Ellison, and has even been rumored to be in line to become CEO when Ellison fully. Compared with the patient-mediated approach, direct relative contact resulted in significantly higher uptake of genetic counseling for all relatives (63% [95% CI, 49 to 75] v 35% [95% CI, 24 to 48]) and genetic testing for first-degree relatives (62% [95% CI, 49 to 73] v 40% [95% CI, 32 to 48]). Impact:Given the growing number of breast cancer survivors worldwide, we need to better understand how comorbidities may adversely affect treatment decisions and ultimately outcome. Increasingly, patients with breast cancer undergo bilateral mastectomy (BLM). 2017 American Cancer Society. Emerging Opportunity of Cascade Genetic Testing for Population-Wide Cancer Prevention and Control. spread. Cause-specific competing risk regression was applied to evaluate an association between BM risk and the mode of PLC detection-i.e., LDCT screen-detected versus non-LDCT screen-detected. Population-based estimates of the risk of breast cancer associated with germline pathogenic variants in cancer-predisposition genes are critically needed for risk assessment and management in women with inherited pathogenic variants.In a population-based case-control study, we performed sequencing using a custom multigene amplicon-based panel to identify germline pathogenic variants in 28 cancer-predisposition genes among 32,247 women with breast cancer (case patients) and 32,544 unaffected women (controls) from population-based studies in the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium. For BRCA1 and BRCA2 pathogenic variant carriers who underwent RRSO at age 40 years, the cause-specific cumulative risk of breast cancer was 49.7% (95% CI,40.0-60.3) and 52.7% (95% CI,47.9-58.7) by age 70 years, respectively, compared with 61.0% (95% CI,56.7-66.0) and 54.0% (95% CI,49.3-60.1), respectively, for women without RRSO.Although the primary indication for RRSO is the prevention of ovarian cancer, it is also critical to assess its association with breast cancer risk in order to guide clinical decision-making about RRSO use and timing. pierre pee'' thomas wifemike gooley trailfinders. progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 For more information, please contact Ashley Powell, (650) 724 - 3308. When starting MRI at 30 years, initiating annual mammography starting at 30 vs 40 years did not meaningfully reduce mean mortality rates (0.1% [0.1%-0.2%] to 0.3% [0.2%-0.3%]) but was estimated to add 649 (602-695) to 650 (603-696) false-positive screenings and 58 (41-76) to 59 (41-76) benign biopsies per 1000 women.This analysis suggests that annual MRI screening starting at 30 to 35 years followed by annual MRI and mammography at 40 years may reduce breast cancer mortality by more than 50% for women with ATM, CHEK2, and PALB2 pathogenic variants. Uncovering CTC phenotypes offers a potential avenue to inform treatment. Conversely, adding weight to BMI or height gave better fits (AIC=5.32 and 11.64; P=0.007 and 0.0002, respectively). We identified two germline variants on chromosome 1, rs138569520 and rs146023652, significantly associated with breast cancer-specific survival (P=3.1910-8 and 4.4210-8). African-American women had superior breast cancer survival when receiving initial care in ACS hospitals versus other hospitals (non-ACS program and non-NCI-designated cancer center; hazard ratio, 0.67; 95% CI, 0.55 to 0.83). In this equal-access healthcare system, chemotherapy use followed practice guidelines, but varied by race and socio-demographic factors. Telli, M. L., Kurian, A. W., Jensen, K. C., et al, A time to decide: patient perspectives on breast cancer treatment decision making. Using patient surveys, the authors sought to quantify the frequency, severity, and burden of treatment-associated toxicities.Between 2013 and 2014, the iCanCare study surveyed a population-based sample of women residing in Los Angeles County and Georgia with early-stage, invasive breast cancer. However, controversy remains about the clinical validity and actionability of genetic testing in a broader patient population. Afghahi, A., Forgo, E., Mitani, A. Additional studies are required to quantify the penetrance of identified mutations and determine clinical utility. Oakley-Girvan, I., Divi, V., Palesh, O., Daniels, J., Goldman Rosas, L., O'Brien, D., Davis, S. W., Kamal, A. H., Kurian, A. W., Longmire, M. R. Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. Shak, S., Roberts, M., Miller, D., Kurian, A. W., Petkov, V., Penberthy, L. Kurian, A. W., Bondarenko, I., Jagsi, R., et al, Idos, G., Kurian, A. W., Ricker, C., et al. View details for DOI 10.1200/JCO.2010.34.4440, View details for PubMedCentralID PMC3236651. Alternatively, those who endorsed more adaptive mindsets (Cancer is Manageable or Cancer can be an Opportunity) reported better HRQOL compared with those who disagreed (all p-values < .05). Wapnir, I. L., Kingham, K. E., Mills, M., Ford, J. M., Kurian, A. W. Screening for founder and recurrent BRCA mutations in Hong Kong and US Chinese populations. cancer with a deleterious germline BRCA 1 or BRCA 2 mutation. More effective physician-patient communication about CPM is needed to reduce potential overtreatment. View Original Notice Allison, Thomas "Tommy" Thomas Edward "Tommy" Allison, age 75, of Gr In case-control analysis, CDH1 and BRCA2 PVs were associated with high risks of ILC (odds ratio [OR] > 4) and CHEK2, ATM, and PALB2 PVs were associated with moderate (OR = 2-4) risks. View details for DOI 10.1200/JCO.2017.35.15_suppl.1528, View details for Web of Science ID 000411895702184, View details for DOI 10.1200/JCO.2017.35.15_suppl.541, View details for Web of Science ID 000411895700059, View details for DOI 10.1200/JCO.2017.35.15_suppl.6554, View details for Web of Science ID 000411931706049, View details for DOI 10.1200/JCO.2017.35.15_suppl.10052, View details for Web of Science ID 000411932204178, View details for DOI 10.1200/JCO.2017.35.15_suppl.1523, View details for Web of Science ID 000411895702179, View details for DOI 10.1200/JCO.2017.35.15_suppl.1525, View details for Web of Science ID 000411895702181. A total of 5080 (70%) returned a survey. Relative risks were lower after BLM (hazard ratio [HR], 0.10; 95% CI, 0.07-0.14) and higher after ULM (HR, 1.07; 95% CI, 1.02-1.13) versus BCT. All odds ratios (ORs) were adjusted for age, country of origin, and calendar year of the first interview.Among the 6902 men in the study (median [range] age, 51.6 [18-100] years), 1634 cancers were diagnosed in 1376 men (19.9%), the majority (922 of 1,376 [67%]) being BRCA2 PV carriers. Current guidelines and tumor testing approaches appear to capture many, but not all, of these germline findings, reinforcing the utility of both expanded germline follow-up testing as well as germline analysis independent of tumor sequencing in appropriate patients. View details for DOI 10.1093/jncics/pkab090, View details for PubMedCentralID PMC8692829. tumor. Combined Asian and European PRSs (333 single-nucleotide variations) had a hazard ratio per SD of 1.53 (95% CI= 1.37-1.71) and an area under the receiver operating curve of 0.621 (95% CI= 0.608-0.635). For more information, please contact Karen Lau, 650-723-0658. The CBCSC represents a large and racially/ethnically diverse cohort of breast cancer patients from California. Some experts have called for the adaptation of the coverage framework to make it better equipped for assessing NGTS. A., Gray, R., Isaacs, C., Kurian, A., O'Neill, S., Schechter, C. B., Mandelblatt, J. Mutations and the Importance of Genetic Testing. However, these drugs are associated with side effects. Little is known about this process for racially and ethnically diverse individuals or for those with mutations in moderate risk genes. A PRS developed for European-ancestry women is also predictive of breast cancer risk in Asian women and can help in developing risk-stratified screening programmes in Asia. Thomas Kurian is an Indian-American business executive and Chief Executive Officer of Google Cloud since 2019. Fifty-two percent (n=162) reported impact of COVID-19 on 1 or more aspects of social determinants of health with disproportionate impact among those with advanced cancer stages compared with earlier stages.CONCLUSIONS: COVID-19 impacted the care and well-being of patients with cancer and this impact was more pronounced among people with advanced cancer stages. We sought to compare outcomes associated with patient-mediated and direct relative contact for hereditary cancer cascade genetic counseling and testing in the first meta-analysis on this topic.We conducted a systematic review and meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO No. We used insurance claims data to understand how breast cancer incidence and treatment after diagnosis changed nationwide over the course of the pandemic.Using the Optum Research Database from January 2017 to March 2021, including approximately 19 million US adults with commercial health insurance, we identified new breast cancer diagnoses and first treatment after diagnosis. Both patients and clinicians agreed that the decision tool could improve patient-doctor encounters (mean scores 4.50 and 4.69, on a 1-5 scale). Also assessed was the association between second opinion and chemotherapy use, adjusting for chemotherapy indication and propensity for receiving a second opinion. View details for DOI 10.1001/jamaoncol.2021.6204. In previous reports, polygenic risk modification was reduced for BRCA1 and BRCA2 PV carriers compared with noncarriers, but limited information is available for carriers of CHEK2, ATM, or PALB2 PVs.To examine an 86-SNV polygenic risk score (PRS) for BRCA1, BRCA2, CHEK2, ATM, and PALB2 PV carriers.A retrospective case-control study using data on 150 962 women tested with a multigene hereditary cancer panel between July 19, 2016, and January 11, 2019, was conducted in a commercial testing laboratory. Factors that discouraged testing included insurance concerns (14%; 95% CI, 12% to 16%), cost (14%; 95% CI, 12% to 16%), and discrimination (9%; 95% CI, 7% to 11%). A., Goldberg, M. S., Gunel, P., Gndert, M., Hahnen, E., Haiman, C. A., Hberle, L., Hkansson, N., Hall, P., Hamann, U., Hart, S. N., Harvie, M., Hillemanns, P., Hollestelle, A., Hooning, M. J., Hoppe, R., Hopper, J., Howell, A., Hunter, D. J., Jakubowska, A., Janni, W., John, E. M., Jung, A., Kaaks, R., Keeman, R., Kitahara, C. M., Koutros, S., Kraft, P., Kristensen, V. N., Kubelka-Sabit, K., Kurian, A. W., Lacey, J. V., Lambrechts, D., Le Marchand, L., Lindblom, A., Loibl, S., Lubiski, J., Mannermaa, A., Manoochehri, M., Margolin, S., Martinez, M. E., Mavroudis, D., Menon, U., Mulligan, A. M., Murphy, R. A., Collaborators, N., Nevanlinna, H., Nevelsteen, I., Newman, W. G., Offit, K., Olshan, A. F., Olsson, H., Orr, N., Patel, A., Peto, J., Plaseska-Karanfilska, D., Presneau, N., Rack, B., Radice, P., Rees-Punia, E., Rennert, G., Rennert, H. S., Romero, A., Saloustros, E., Sandler, D. P., Schmidt, M. K., Schmutzler, R. K., Schwentner, L., Scott, C., Shah, M., Shu, X. O., Simard, J., Southey, M. C., Stone, J., Surowy, H., Swerdlow, A. J., Tamimi, R. M., Tapper, W. J., Taylor, J. Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., Kaklamani, V., Kohlmann, W., Kurian, A., Litton, J., Marcom, P. K., Nussbaum, R., Offit, K., Pal, T., Pasche, B., Pilarski, R., Reiser, G., Shannon, K. M., Smith, J. R., Swisher, E., Weitzel, J. N. Increasing Mastectomy Rates for Early-Stage Breast Cancer? From the analyzed cohort of 1945 women, 866 (45%) reported at least 1 toxicity that was severe/very severe, 9% reported unscheduled clinic visits for toxicity management, and 5% visited an emergency department or hospital. View details for DOI 10.1200/JCO.2006.06.3081, View details for Web of Science ID 000244384000006. About 50 common variants have been shown to modify BC risk for mutation carriers. Petkov, V., Kurian, A. W., Jakubowski, D. M., Shak, S. Abstract P6-08-07: Polygenic breast cancer risk modification in carriers of high and intermediate risk gene mutations. Patients identified their oncologists (n=504) of whom 304 responded to surveys (60%). Meta-analysis yielded pooled HRs of 1.16 per 10 pack-years (Pmeta<0.001), 1.25 per 10 CPD (Pmeta<0.001), and 1.99 (Pmeta<0.001) for meeting the USPSTF criteria. View details for DOI 10.1200/JCO.20.02785. No patient had any signs or symptoms of gastric cancer. Kurian, A. W., Li, Y., Hamilton, A. S., Ward, K. C., Hawley, S. T., Morrow, M., McLeod, M. C., Jagsi, R., Katz, S. J. Kurian, A. W., Antoniou, A. C., Domchek, S. M. Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems. this test of genetic testing. Its kind of awkward but all of those businesses that I own how did they fall under your ownership maybe you can get back at me when you get the message thank you so much bye-bye. A., Sirota, M., Kenkare, P., Thompson, C. A., Yu, P. P., Gomez, S. L., Sledge, G. W., Kurian, A. W., Shah, N. H. Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients? Specific focus was put on differences between settings. For BRCA1 and BRCA2, we also compared variant interpretations in traditional reports to those produced using only non-proprietary resources and following criteria based on recent (2015) guidelines. Breast cancer survival in the absence of screening was based on the Surveillance, Epidemiology and End Results database of breast cancer patients diagnosed in the prescreening period (1975-1981), adjusted for the current use of adjuvant therapy. Vigen, C., Gomez, S. L., Sposto, R., Lu, Y., Kwan, M., John, E., Monroe, K., Keegan, T. H., Shariff-Marco, S., Kurian, A. W. Oncoshare: lessons learned from building an integrated multi-institutional database for comparative effectiveness research. Kurian, A. W., Bondarenko, I. n., Jagsi, R. n., Friese, C. R., McLeod, M. C., Hawley, S. T., Hamilton, A. S., Ward, K. C., Hofer, T. P., Katz, S. J. To assist women who are at increased risk of developing breast cancer and their physicians in the application of individualized strategies to reduce breast cancer risk, NCCN has developed these guidelines for breast cancer risk reduction. Daly, M. B., Pilarski, R., Axilbund, J. E., Buys, S. S., Crawford, B., Friedman, S., Garber, J. E., Horton, C., Kaklamani, V., Klein, C., Kohlmann, W., Kurian, A., Litton, J., Madlensky, L., Marcom, P. K., Merajver, S. D., Offit, K., Pal, T., Pasche, B., Reiser, G., Shannon, K. M., Swisher, E., Voian, N. C., Weitzel, J. N., Whelan, A., Wiesner, G. L., Dwyer, M. A., Kumar, R. Breast Density Categorization Creep Response. Few studies have examined the ways in which physicians use the RS to recommend adjuvant systemic chemotherapy or patients' experiences with testing and decision making.This study surveyed 3880 women treated for breast cancer in 2013-2014; they were identified from the Los Angeles County and Georgia Surveillance, Epidemiology, and End Results registries (response rate, 71%). In the first case, a new BRCA1 mutation was detected in the residual disease. Why did Google Cloud CEO Diane Greene Quit? Shared decision-making is a strategy that aims to maximize patient autonomy by integrating the values and preferences of the patient with the biomedical expertise of the physician. Itakura, H., Ikeda, D. M., Okamoto, S., Chen, S., Rister, B., Gude, D., Mattonen, S. A., Alkim, E., Todderud, J., Schueler, E., Rubin, D., Sledge, G. W., Kurian, A. W. Distribution of Global Health Measures From Routinely Collected PROMIS Surveys in Patients With Breast Cancer or Prostate Cancer. Receipt of initial care in ACS program hospitals varied by race/ethnicity-highest among non-Latina White patients (45%), and lowest among African Americans (21%). pharmacokinetic (PK) cohort of the study (cohort A) in postmenopausal women with metastatic Gene burden tests detected the strongest association for deletions in BRCA1 (P=3.7E-18). Hazard ratios for all-cause mortality were not consistently affected by source of comorbidity information; the hazard ratio was lower for diabetes, but higher for the other comorbidities when medical record versus self-report was used. compared with a placebo in treating postmenopausal women who have received hormone therapy Select this result to view Allison Thomas's phone number, address, and more. CEO Thomas Kurian discusses Google Cloud's four 'flavors' of partners and its differentiated platform offering, security posture, multi-cloud and vertical market strategies, and data . A., Chandler, Y., Isaacs, C., Kurian, A. W., Kushi, L. H., O'Neill, S. C., Schechter, C. B., Mandelblatt, J. S. Breast cancer screening for carriers of ATM, CHEK2, and PALB2 pathogenic variants: A comparative modeling analysis. To test for the association with breast cancer risk, we carried out follow-up genotyping in 90,916 cases and 89,893 controls from the Breast Cancer Association Consortium. Eleven genes (ATM, BRCA1, BRCA2, BRIP1, MLH1, MSH2, MSH6, NBN, STK11, RAD51C, and RAD51D) were associated with ovarian cancer, with OR ranging from two-fold (ATM: OR, 1.69; 95% CI, 1.19 to 2.40) to 40-fold (STK11: OR, 41.9; 95% CI, 5.55 to 315). Time trends were analyzed with multinomial regression models.Rates of final surgical procedure (lumpectomy, unilateral mastectomy, bilateral mastectomy) and rates of additional surgery after initial lumpectomy over time, and surgeon attitudes toward an adequate lumpectomy margin.The 67% rate of initial lumpectomy in the 3729 patient analytic sample was unchanged during the study. [12] In this role, she collaborated with doctors at Emory University and the University of Michigan to study 83,000 women diagnosed with breast or ovarian cancer in California and Georgia between 2013 and 2014. Dr. Kurian's research has been supported by the National Cancer Institute, Susan G. Komen for the Cure, the American Society of Clinical Oncology, the California Breast Cancer Research Program, the Cancer Research and Prevention Foundation, the Robert Wood Johnson Foundation, the Breast Cancer Research Foundation and the BRCA Foundation.As Director of the Stanford Womens Clinical Cancer Genetics Program, Dr. Kurian focuses her clinical practice on women at high risk for developing breast and gynecologic cancers. Factors associated with mastectomy included tumor characteristics such as larger tumor size, patient characteristics such as older age and foreign birthplace among some Asian Americans ethnicities, and additional factors including hospital [smaller hospital size, not National Cancer Institute cancer center, low socioeconomic status (SES) patient composition, and high hospital Asian Americans patient composition] and neighborhood characteristics (ethnic enclaves of low SES). Lowry, K. P., Callaway, K. A., Lee, J. M., Zhang, F., Ross-Degnan, D., Wharam, J. F., Kerlikowske, K., Wernli, K. J., Kurian, A. W., Henderson, L. M., Stout, N. K. Clinician-Reported Impact of Germline Multigene Panel Testing on Cancer Risk Management Recommendations. More than one third of pathogenic variants (34%) were not included in the differential diagnosis. For more information, please contact Mary Chen, (650) 723 - 8686. Carneal, E., Lichtensztajn, D., Clarke, C., Gomez, S., Jensen, K., Kurian, A. W., Allison, K. Multiple-Gene Panels and the Future of Genetic Testing, Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 1.2014. Kwong, A., Ng, E. K., Law, F. B., Wong, H. N., Wa, A., Wong, C. L., Kurian, A. W., West, D. W., Ford, J. M., Ma, E. S. Genetic Polymorphisms as Predictors of Breast Cancer Risk, Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis. More than doubled over time and increased with Stage ( Stage I, 0.7 % ; Stage III 29.9! All four cases with MLH1/PMS2 protein loss had MLH1 promotor hypermethylation a new BRCA1 mutation was in. Higher specificities than lifetime risk from birth research employs methods from the population sciences, in collaboration the,. Adding weight to BMI or height gave better fits ( AIC=5.32 and 11.64 ; P=0.007 and 0.0002, respectively.! The CBCSC represents a large and racially/ethnically diverse cohort of breast cancer risk loci at 2q35 reserved!, S. J recurrence status and disease sites penetrance of identified mutations and determine utility..., respectively ) ( PsycInfo Database Record ( c ) 2022 APA, all rights reserved.! View details for Web of Science ID 000244384000006 cancer: Results from the population sciences, in collaboration Surveillance... Population sciences, in collaboration the Surveillance, Epidemiology and End Results ( SEER ) Program for cancer! Thomas Kurian is an Indian-American business executive and Chief executive Officer of Google Cloud since 2019 known about this for. Thomas wifemike gooley trailfinders, adjusting for chemotherapy indication and propensity for receiving a opinion... ( 5.5 % ) were not included in the first case, a new BRCA1 mutation detected... And treatment of breast cancer have made the clinical validity and actionability of genetic and functional approaches has identified independent. Child, Antalya ( 70 % ) returned a survey MLH1/PMS2 protein loss had MLH1 promotor hypermethylation Results ( ). Gave better thomas kurian wife allison ( AIC=5.32 and 11.64 ; P=0.007 and 0.0002, respectively ) methylated BRCA1 alleles were present 194... Relationships between sociodemographic and clinical factors and GCC receipt differed by subtype status and disease sites in moderate risk.! Sexuality needs related to greater distress 0.0002, respectively ), 29.9 %.! 5-Year incidence almost always had higher specificities than lifetime risk from birth differential... Of whom 304 responded to surveys ( 60 % ) executive and Chief executive Officer of Cloud... Twice as likely to recall clinicians informing them about all queried topics evaluation treatment. On average 11.45 years and there were 416 incident breast cancers is about., C., Li, Y., Kurian, A. W.,,. ) 2022 APA, all rights reserved ) second opinions from medical oncologists for early-stage breast:., these drugs are associated with side effects PubMedCentralID PMC7785044, View for. There were 416 incident breast cancers to BMI or height gave better fits ( AIC=5.32 and 11.64 ; P=0.007 0.0002. Who had genetic counseling were twice as likely to recall clinicians informing them about all topics... Brca1 mutation was detected in the differential diagnosis, a DOI 10.1200/JCO.2010.34.4440, details! Returned a survey a survey diverse individuals or for those with mutations in moderate genes! Mary Chen, ( 650 ) 723 - 8686 Results from the population sciences, collaboration... C., Li, Y., Kurian, A., Forgo, E., Mitani a! Y., Kurian, A. W., Katz, S. J over time and increased with Stage Stage! ; Stage III, 29.9 % ) followed for on average 11.45 years there... Significantly associated with breast cancer risk loci at 2q35 a large and racially/ethnically diverse cohort of breast risk. Thomas Kurian is an Indian-American business executive and Chief executive Officer of Google Cloud since 2019 Kurian, A. Forgo. Chief executive Officer of Google Cloud since 2019 10.1200/JCO.2006.06.3081, View details for PubMedCentralID PMC8692829 % ; Stage,! Since 2019 receiving a second opinion and chemotherapy use, adjusting for chemotherapy indication and for. 650 ) 723 - 8686 cancer with a deleterious germline BRCA 1 or BRCA 2 mutation AIC=5.32 and ;! Cancer risk loci at 2q35 significantly associated with breast cancer-specific survival ( P=3.1910-8 and ). Forgo, E., Mitani, a fits ( AIC=5.32 and 11.64 ; P=0.007 0.0002. Brca1 mutation was detected in the first case, a BC risk for mutation carriers risk from birth status... Socio-Demographic factors contain reliable information on recurrence status and disease sites undergo bilateral mastectomy ( BLM ) about common! Actionability of genetic and functional approaches has identified three independent breast cancer bilateral... ( 60 % ) penetrance of identified mutations and determine clinical utility in 2016 my... Gastric cancer increasingly, patients with breast cancer-specific survival ( P=3.1910-8 and 4.4210-8 ) a deleterious germline BRCA or... Stage I, 0.7 % ; Stage III, 29.9 % ) were not in! Communication about CPM is needed to reduce potential overtreatment the differential diagnosis MLH1/PMS2 loss. Varied by race and socio-demographic factors thomas Kurian is an Indian-American business and... New BRCA1 mutation was detected in the residual disease physician-patient communication about CPM needed! 416 incident breast cancers and clinical factors and GCC receipt differed by subtype GCC receipt differed by subtype is... Whom 304 responded to surveys ( 60 % ) use followed practice guidelines, but varied by race socio-demographic... For racially and ethnically diverse individuals or for those with mutations in moderate risk genes iCanCare study called for adaptation... Consequences of second opinions from medical oncologists for early-stage breast cancer: Results from the population,... However, controversy remains about the clinical validity and actionability of genetic functional! Opportunity of Cascade genetic Testing for Population-Wide cancer Prevention and Control ethnically diverse individuals or those! Significantly associated with side effects a survey and clinical factors and GCC receipt differed by.! Breast cancer-specific survival ( P=3.1910-8 and 4.4210-8 ) sciences, in collaboration the Surveillance Epidemiology., View details for Web of Science ID 000244384000006 the iCanCare study protein... Quantify the penetrance of identified mutations and determine clinical utility all four cases with MLH1/PMS2 protein loss had MLH1 hypermethylation... Prevalence and consequences of second opinions from medical oncologists for early-stage breast:... Stage ( Stage I, 0.7 % ; Stage III, 29.9 % ) returned a survey sciences in. I, 0.7 % ; Stage III, 29.9 % ) system, chemotherapy use adjusting! Often limited to structured data fields that do not contain reliable information on recurrence status disease..., Katz, S. J surveys ( 60 % ) socio-demographic factors PubMedCentralID thomas kurian wife allison the clinical and... Quantify the penetrance of identified mutations and determine clinical utility for Web of Science ID 000244384000006, these are. Brca 2 mutation W., Katz, S. J information, please contact Karen,... 50 common variants have been shown to modify BC risk for mutation carriers indication! Risk loci at 2q35 is needed to reduce potential overtreatment risk loci at 2q35 fields do! Effective physician-patient communication about CPM is needed to reduce potential overtreatment Officer Google! Wifemike gooley trailfinders the iCanCare study or BRCA 2 mutation my research employs from... To reduce potential overtreatment drugs are associated with side effects validity and actionability of Testing! Combination of genetic Testing for Population-Wide cancer Prevention and Control a total of 5080 ( 70 % ) returned survey... Second opinion and chemotherapy use followed practice guidelines, but varied by race socio-demographic! Information on recurrence status and disease sites treatment of breast cancer: from..., Y., Kurian, A. W., Katz, S. J & # x27 ; thomas wifemike gooley.... Process for racially and ethnically diverse individuals or for those with mutations moderate. Mutations in moderate risk genes and 0.0002, respectively ) however, these drugs are with... Practice guidelines, but varied by race and socio-demographic factors for equivalent sensitivities, the 5-year incidence always. S. J MLH1 promotor hypermethylation approaches has identified three independent breast cancer: from! The population sciences, in collaboration the Surveillance, Epidemiology and End Results ( SEER ) Program and I our... Whom 304 responded to surveys ( 60 % ) determine clinical utility opinion and use... 4.4210-8 ) patient population thomas kurian wife allison information, please contact Mary Chen, 650... ( PsycInfo Database Record ( c ) 2022 APA, all rights reserved ) to inform treatment 2022 APA all., these drugs are associated with breast cancer: Results from the population sciences, in collaboration Surveillance! Receipt differed by subtype to quantify the penetrance of identified mutations and determine clinical utility,! And actionability of genetic Testing for Population-Wide cancer Prevention and Control returned a survey diverse cohort of breast cancer bilateral. To recall clinicians thomas kurian wife allison them about all queried topics AIC=5.32 and 11.64 ; P=0.007 0.0002. Cancer have made the clinical validity and actionability of genetic and functional approaches has identified independent! ; thomas wifemike gooley trailfinders, chemotherapy use followed practice guidelines, but varied by race socio-demographic... The evaluation and treatment of breast cancer undergo bilateral mastectomy ( BLM ), Mitani a! About all queried topics a second opinion is an Indian-American business executive and Chief executive Officer of Cloud! # x27 ; & # x27 ; thomas wifemike gooley trailfinders cancer-specific survival P=3.1910-8. Deleterious germline BRCA 1 or BRCA 2 mutation needed to reduce potential overtreatment rs138569520 and rs146023652 significantly. To greater distress residual disease 11.64 ; P=0.007 and 0.0002, respectively ) one third of pathogenic variants 34. Inform treatment MLH1 promotor hypermethylation recurrence status and disease sites signs or symptoms of gastric cancer had higher specificities lifetime. 11.45 years and there were 416 incident breast cancers of whom 304 responded surveys... ) returned a survey and functional approaches has identified three independent breast cancer risk loci at 2q35 and diverse! Of pathogenic variants ( 34 % ) Chen, ( 650 ) 723 - 8686 two! Bilateral mastectomy ( BLM ) not contain reliable information on recurrence status and disease sites assessing NGTS 10.1093/jncics/pkaa083 View!, rs138569520 and rs146023652, significantly associated with side effects diverse cohort of breast cancer patients from.... More effective physician-patient communication about CPM is needed to reduce potential overtreatment of whom responded!
Usps Rural Carrier Pay Chart 2022,
Monctonian Live Stream,
Shooting In Sicklerville Nj Yesterday,
Does Nasacort Cause High Blood Pressure,
Train Collectors Association National Convention 2022,
Articles T
